BioVie Inc.
BIVIHealthcare|Biotechnology|US
$1.33
+0.12 (+9.92%)
DCF Value
$1200941.90
Tangible Book / Share
$0.75
Cash / Share
$0.94
Financials
Financial Snapshot
Market Cap
$11.3M
Enterprise Value
$3.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$22.6M
Cash & Investments
$7.7M
Net Cash
$7.5M
Free Cash Flow (TTM)
-$18.9M
Operating CF (TTM)
-$18.9M
Debt/Equity
0.04
Cash Runway & Burn Rate
Cash on Hand
$7.7M
Quarterly Burn
$4.7M
Monthly Burn
$1.6M
Est. Runway
~1.6 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $5.1K | $45.8K | $339.9K | $37.2K | $4.5M | $18.6M | $33.9M | $23.8M | $17.5M | $8977.37B | $7.7M | |
| Operating Cash Flow | -$623.6K | -$621.3K | -$2.5M | -$1.6M | -$10.5M | -$19.0M | -$40.3M | -$27.9M | -$19.0M | -$19.02B | -$18.9M | |
| Free Cash Flow | -$623.6K | -$621.3K | -$2.5M | -$1.6M | -$10.5M | -$19.0M | -$40.3M | -$27.9M | -$19.0M | -$19.02B | -$18.9M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.00 | $0.00 | $0.00 | -$4.00 | |
| Financing Cash Flow | $505.0K | $662.0K | $2.8M | $1.3M | $14.9M | $33.1M | $55.4M | $17.8M | $12.7M | $10.46B | $1.7M |
R&D Spending
R&D (TTM)
$14.4M
R&D Intensity
—
R&D Growth vs Prior
+2.9%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $466.4K | $370.9K | $1.0M | $1.2M | $133.2M | $17.3M | $33.3M | $23.1M | $9.3M | $14.0M | $14.4M | |
| SG&A | $857.9K | $1.8M | $1.3M | $0.00 | $0.00 | $0.00 | $11.6M | $0.00 | $8.6M | $8.5M | $8.5M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $229.4K | $0.00 | $121.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$229.4K | $0.00 | -$121.0K | |
| R&D | $466.4K | $370.9K | $1.0M | $1.2M | $133.2M | $17.3M | $33.3M | $23.1M | $9.3M | $14.0M | $14.4M | |
| SG&A | $857.9K | $1.8M | $1.3M | $0.00 | $0.00 | $0.00 | $11.6M | $0.00 | $8.6M | $8.5M | $8.5M | |
| Operating Income | -$1.6M | -$2.4M | -$2.5M | -$2.7M | -$138.1M | -$27.3M | -$45.1M | -$32.2M | -$18.1M | -$22.7M | -$23.0M | |
| Interest Expense | $0.00 | $41.0K | $273.00 | $4.8M | $559.5K | $2.2M | $4.3M | $2.9M | $332.7K | $17.9K | $16.9K | |
| Pretax Income | -$1.3M | -$2.4M | -$2.4M | -$16.7M | -$130.2M | -$26.1M | -$50.3M | -$32.1M | -$17.5M | -$22.1M | -$22.6M | |
| Net Income | -$1.3M | -$2.4M | -$2.4M | -$16.7M | -$130.2M | -$26.1M | -$50.3M | -$32.1M | -$17.5M | -$22.1M | -$22.6M | |
| EPS (Diluted) | -186.10 | -317.70 | -98.20 | -685.20 | -1482.30 | -106.00 | -154.70 | -73.05 | -12.12 | -3.05 | -2.90 | |
| EBITDA | -$1.3M | -$2.1M | -$2.3M | -$2.5M | -$129.5M | -$23.7M | -$45.7M | -$29.0M | -$17.0M | -$21.9M | -$22.6M | |
| Shares Out. (M) | 0.01 | 0.01 | 0.03 | 0.05 | 0.12 | 0.25 | 0.32 | 0.45 | 1.48 | 7.25 | 8.27 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.1K | $45.8K | $339.9K | $37.2K | $4.5M | $18.6M | $19.5M | $23.8M | $17.5M | $8977.37B | $7.7M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $14.5M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $5.1K | $45.8K | $674.1K | $413.0K | $4.6M | $18.8M | $34.0M | $24.0M | $20.7M | $13642.17B | $10.5M | |
| Total Assets | $2.4M | $2.2M | $2.6M | $2.1M | $6.0M | $20.1M | $35.1M | $25.2M | $21.6M | $14250.46B | $11.0M | |
| Total Current Liabilities | $631.0K | $1.2M | $443.5K | $23.5M | $996.4K | $4.2M | $14.5M | $9.4M | $2.3M | $3795.77B | $4.4M | |
| Long-Term Debt | $575.9K | $825.9K | $0.00 | $62.5K | $0.00 | $12.1M | $5.2M | $0.00 | $0.00 | $184.42B | $158.8K | |
| Total Liabilities | $1.2M | $2.1M | $443.5K | $23.6M | $996.4K | $16.4M | $19.8M | $9.7M | $2.6M | $3980.19B | $4.5M | |
| Stockholders' Equity | $1.2M | $111.2K | $2.1M | -$21.5M | $5.1M | $3.7M | $15.3M | $15.5M | $19.0M | $10270.27B | $6.5M | |
| Retained Earnings | -$2.3M | -$4.8M | -$7.3M | -$41.0M | -$224.9M | -$251.0M | -$301.2M | -$334.2M | -$352.1M | -$374260.65B | -$379.9M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$623.6K | -$621.3K | -$2.5M | -$1.6M | -$10.5M | -$19.0M | -$40.3M | -$27.9M | -$19.0M | -$19.02B | -$18.9M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.00 | $0.00 | $0.00 | -$4.00 | |
| Free Cash Flow | -$623.6K | -$621.3K | -$2.5M | -$1.6M | -$10.5M | -$19.0M | -$40.3M | -$27.9M | -$19.0M | -$19.02B | -$18.9M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$14.3M | $14.5M | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $505.0K | $662.0K | $2.8M | $1.3M | $14.9M | $33.1M | $55.4M | $17.8M | $12.7M | $10.46B | $1.7M | |
| Issuance of Stock | $480.0K | $447.0K | $1.2M | $0.00 | $15.6M | $18.5M | $55.4M | $27.8M | $15.7M | $10.46B | $10.6M | |
| Repurchase of Stock | $0.00 | $0.00 | -$1.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | -$35.0K | -$244.3K | $1.3M | -$1.4M | $14.6M | $0.00 | -$10.0M | -$5.8M | $0.00 | $0.00 | |
| Stock Based Comp. | $92.1K | $893.5K | $64.9K | $24.8K | $3.0M | $6.2M | $6.4M | $4.7M | $2.5M | $2.87B | $2.3M | |
| Net Change in Cash | -$118.6K | $40.7K | $294.1K | -$302.7K | $4.5M | $14.1M | $819.2K | $4.4M | -$6.3M | -$8.57B | -$17.2M |
Dilution Tracker
Shares outstanding grew 5742.0% over 5 years — significant dilution
Shares Outstanding
9M
5-Year Share Growth
+5742.0%
Stock Issuance (TTM)
$10.6M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.01 | 0.01 | 0.03 | 0.05 | 0.12 | 0.25 | 0.32 | 0.45 | 1.48 | 7.25 | 8.27 | |
| Change vs Prior % | — | 7.1% | 231.5% | 94.1% | 151.6% | 98.8% | 31.7% | 39.1% | 227.0% | 390.5% | 14.1% | |
| Stock Issuance | $480.0K | $447.0K | $1.2M | $0.00 | $15.6M | $18.5M | $55.4M | $27.8M | $15.7M | $10.46B | $10.6M | |
| Stock Repurchase | $0.00 | $0.00 | -$1.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $92.1K | $893.5K | $64.9K | $24.8K | $3.0M | $6.2M | $6.4M | $4.7M | $2.5M | $2.87B | $2.3M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -115.0% | -2170.0% | -114.7% | 77.6% | -2579.0% | -710.6% | -327.6% | -207.1% | -92.3% | -0.0% | -174.9% | |
| ROA % | -56.3% | -110.9% | -94.9% | -800.3% | -2154.1% | -129.7% | -143.2% | -127.4% | -81.4% | -0.0% | -204.7% | |
| ROIC % | -87.9% | -253.1% | -117.2% | 13.1% | -2733.6% | -170.5% | -151.5% | -148.9% | -93.3% | -0.0% | -339.3% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | |
| Operating Income | -259.7% | -52.6% | -5.3% | -7.8% | -5026.6% | 80.3% | -65.4% | 28.6% | 43.9% | -25.4% | |
| Net Income | -208.2% | -81.3% | -1.3% | -582.4% | -681.0% | 80.0% | -92.7% | 36.1% | 45.4% | -25.8% | |
| EPS (Diluted) | -200.6% | -70.7% | 69.1% | -597.8% | -116.3% | 92.8% | -45.9% | 52.8% | 83.4% | 74.8% | |
| Operating Cash Flow | -281.1% | 0.4% | -302.6% | 34.9% | -542.0% | -81.7% | -112.0% | 30.6% | 31.9% | -99897.9% | |
| Free Cash Flow | -281.1% | 0.4% | -302.6% | 34.9% | -542.0% | -81.7% | -112.0% | 30.6% | 31.9% | -99897.9% | |
| R&D Expense | 1130.5% | -20.5% | 171.8% | 14.1% | 11475.6% | -87.0% | 92.9% | -30.6% | -59.9% | 50.7% | |
| SG&A Expense | 150.0% | 106.5% | -28.9% | -100.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | -0.7% | |
| Total Assets | -13.1% | -8.0% | 18.3% | -19.1% | 190.2% | 232.7% | 74.5% | -28.2% | -14.5% | 66089921.7% | |
| Book Value / Share | -41.3% | -90.9% | 477.2% | -609.6% | 109.3% | -63.4% | 217.3% | -27.3% | -62.5% | 11014031.3% | |
| Debt | 250.0% | 2259.8% | -100.0% | 0.0% | -100.0% | 0.0% | 17.6% | -57.6% | -94.3% | 78718026.1% | |
| Diluted Shares | 2.5% | 7.1% | 231.5% | 94.1% | 151.6% | 98.8% | 31.7% | 39.1% | 227.0% | 390.5% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.68
10Y Low / Med / High0.00 / 9.74 / 45.53
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1200941.90
Tangible Book / Share
$0.75
Net Current Assets / Share
$0.70
Graham Net-Net
$0.39
Cash / Share
$0.94
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -19.48 | -2.12 | -12.09 | -2.04 | -1.14 | -1.37 | -2.79 | -0.57 | -0.76 | -0.64 | -0.46 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 22.24 | 45.53 | 13.88 | -3.21 | 41.63 | 9.74 | 9.13 | 1.21 | 0.72 | 0.00 | 1.68 | |
| EV/EBITDA | -19.46 | -2.73 | -12.90 | -28.37 | -1.59 | -1.24 | -2.95 | -0.04 | 0.21 | 397772.85 | -0.17 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-52.79
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $367.5M | $0.00 | $0.00 |
| Net Income | -$4.6M | -$4.1M | -$4.0M |
| EPS | $-0.63 | $-0.57 | $-0.55 |
| # Analysts (EPS) | 1 | 1 | 1 |